NOVARTIS PHARMACEUTICALS v. ACCORD HEALTHCARE INC. , No. 21-1070 (Fed. Cir. 2022)
Annotate this CaseThis opinion or order relates to an opinion or order originally issued on January 3, 2022.
Download PDF
Case: 21-1070 Document: 43 Page: 1 Filed: 01/04/2022 NOTE: This order is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ January 4, 2022 ERRATA ______________________ Appeal No. 21-1070 NOVARTIS PHARMACEUTICALS CORPORATION, Plaintiff-Appellee v. ACCORD HEALTHCARE, INC., AUROBINDO PHARMA LTD., AUROBINDO PHARMA USA, INC., DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES, LTD., EMCURE PHARMACEUTICALS LTD., HERITAGE PHARMACEUTICALS INC., GLENMARK PHARMACEUTICALS INC., USA, GLENMARK PHARMACEUTICALS LIMITED, HETERO USA, INC., HETERO LABS LIMITED UNIT-V, HETERO LABS LIMITED, MYLAN PHARMACEUTICALS, INC., PRINSTON PHARMACEUTICAL INC., STRIDES GLOBAL PHARMA PRIVATE LIMITED, STRIDES PHARMA, INC., TORRENT PHARMA INC., TORRENT PHARMACEUTICALS LTD., ZYDUS PHARMACEUTICALS (USA) INC., CADILA HEALTHCARE LTD., APOTEX INC., APOTEX CORP., SUN PHARMACEUTICAL INDUSTRIES, LTD., SUN PHARMACEUTICAL INDUSTRIES INC., Case: 21-1070 2 Document: 43 NOVARTIS PHARMACEUTICALS Page: 2 Filed: 01/04/2022 v. ACCORD HEALTHCARE INC. SUN PHARMA GLOBAL FZE, Defendants HEC PHARM CO., LTD., HEC PHARM USA INC., Defendants-Appellants Decided: January 3, 2022 Precedential opinion ______________________ Please make the following change: Page 2, line 7 (majority opinion): the issuance date of “January 3, 2021” is changed to “January 3, 2022”.
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
